TagCyx is a research based company based in Tokyo (Japan), founded in March 2007 as a spin out company of RIKEN. TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

Chief Executive Officer:

Chizuko Koseki, Ph.D

Board Members:

Akiyoshi Kudose (CFO)
Gen Watanabe (COO)
Maiko Katadae (Non Executive Director)
Mikio Kawahara (Non Executive Director)
Takayuki Okabuchi (Non Executive Director)
Hajime Kurachi (Auditor)
Takahiro Kono (Auditor)
Yoshiyuki Yamakawa (Auditor)